Peña Juan S, Vazquez Maribel
Department of Biomedical Engineering, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA.
Brain Sci. 2020 May 29;10(6):330. doi: 10.3390/brainsci10060330.
Progressive vision loss in adults has become increasingly prevalent worldwide due to retinopathies associated with aging, genetics, and epigenetic factors that damage the retinal microvasculature. Insufficient supply of oxygen and/or nutrients upregulates factors such as vascular endothelial growth factor (VEGF) and epidermal growth factor (EGF), which can induce abnormal angiogenesis and damage the structural arrangement of the retinal blood barrier (BRB). Müller glia (MG) regulate the diffusion of essential compounds across the BRB and respond to retinal insults via reactive gliosis, which includes cell hypertrophy, migration, and/or proliferation near areas of elevated VEGF concentration. Increasing concentrations of exogenous VEGF, upregulated by retinal pigmented epithelium cells, and endogenous epidermal growth factor receptor (EGF-R) stimulation in MG, implicated in MG proliferative and migratory behavior, often lead to progressive and permanent vision loss. Our project examined the chemotactic responses of the rMC-1 cell line, a mammalian MG model, toward VEGF and EGF signaling fields in transwell assays, and within respective concentration gradient fields produced in the glia line (gLL) microfluidic system previously described by our group. rMC-1 receptor expression in defined ligand fields was also evaluated using quantitative polymerase chain reaction (qPCR) and immunocytochemical staining. Results illustrate dramatic increases in rMC-1 chemotactic responses towards EGF gradient fields after pre-treatment with VEGF. In addition, qPCR illustrated significant upregulation of EGF-R upon VEGF pre-treatment, which was higher than that induced by its cognate ligand, EGF. These results suggest interplay of molecular pathways between VEGF and EGF-R that have remained understudied in MG but are significant to the development of effective anti-VEGF treatments needed for a variety of retinopathies.
由于与衰老、遗传和表观遗传因素相关的视网膜病变会损害视网膜微血管,成人进行性视力丧失在全球范围内日益普遍。氧气和/或营养物质供应不足会上调血管内皮生长因子(VEGF)和表皮生长因子(EGF)等因子,这些因子可诱导异常血管生成并破坏视网膜血屏障(BRB)的结构排列。穆勒胶质细胞(MG)调节必需化合物通过BRB的扩散,并通过反应性胶质增生对视网膜损伤作出反应,反应性胶质增生包括细胞肥大、迁移和/或在VEGF浓度升高区域附近增殖。视网膜色素上皮细胞上调的外源性VEGF浓度增加,以及MG中内源性表皮生长因子受体(EGF-R)的刺激,与MG的增殖和迁移行为有关,常常导致进行性和永久性视力丧失。我们的项目在transwell试验中以及在我们小组先前描述的胶质细胞系(gLL)微流控系统中产生的各自浓度梯度场内,研究了哺乳动物MG模型rMC-1细胞系对VEGF和EGF信号场的趋化反应。还使用定量聚合酶链反应(qPCR)和免疫细胞化学染色评估了rMC-1受体在确定配体场中的表达。结果表明,用VEGF预处理后,rMC-1对EGF梯度场的趋化反应显著增加。此外,qPCR显示VEGF预处理后EGF-R显著上调,高于其同源配体EGF诱导的上调。这些结果表明VEGF和EGF-R之间的分子途径相互作用,在MG中尚未得到充分研究,但对于各种视网膜病变所需的有效抗VEGF治疗的开发具有重要意义。